about
Present and future in the treatment of diabetic kidney diseaseCrescentic glomerulonephritis: data from the Spanish Glomerulonephritis Registry.The non-casual relation between eosinophilia and thrombotic microangiopathy.A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic SyndromeRenal biopsy in very elderly patients: data from the Spanish Registry of Glomerulonephritis.Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern.The impact of access blood flow surveillance on reduction of thrombosis in native arteriovenous fistula: a randomized clinical trial.The effect of some medications given to CKD patients on vitamin D levels.Study of glomerulonephritis evolution in Castilla-La Mancha (GLOMANCHA) between 1994 and 2008.Cytomegalovirus encephalitis in a hemodialysis patient: a rare association.[Dyspnea caused by Coxiella Burnetii].Pulmonary hypertension is an independent predictor of cardiovascular events and mortality in haemodialysis patients.A Spanish multicentric study to evaluate the clinical activity of nephrology fellows during in-hospital on-call shifts.[Pulmonary hypertension in hemodialysis patients: Prevalence and associated factors].Dose equivalence between continuous erythropoietin receptor activator (CERA), Darbepoetin and Epoetin in patients with advanced chronic kidney disease.Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease.Increase of ischaemic colitis incidence in haemodialysis.Diastolic dysfunction and high levels of new cardiac biomarkers as risk factors for cardiovascular events and mortality in hemodialysis patients.Detection of patients at high risk for non-occlusive mesenteric ischemia in hemodialysis.Cardiovascular events and mortality in chronic kidney disease (stages I-IV).Asymptomatic Intradialytic Supraventricular Arrhythmias and Adverse Outcomes in Patients on Hemodialysis.Online Hemodiafiltration Reduces Bisphenol A Levels.Albumin leakage in online hemodiafiltration, more convective transport, more losses?Body Composition Affects Urea Distribution Volume Estimated by Watson's Formula.Evaluation of methods based on creatinine and cystatin C to estimate glomerular filtration rate in chronic kidney disease.Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial.Protein-bound toxins: added value in their removal with high convective volumes.Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients.Prevalence and characteristics of patients with resistant hypertension and chronic kidney disease.Diffuse alveolar damage and acute kidney injury induced by abusive use of non-steroidal anti-inflammatory drugs: a new and atypical renopulmonary syndrome?Creatine-kinase and dialysis patients, a helpful tool for stratifying cardiovascular risk?Dialysis catheter related bacteriemia by Gordonia rubropertincta and Sputi in two hemodialysis patients.High-sensitivity troponin T levels in kidney transplant recipients.El bisfenol A: un factor ambiental implicado en el daño nefrovascularAspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study)Follow-up of gestational diabetes insipidus using magnetic resonance imagingRenal infarction in patient with long-standing ventricular aneurysmIntraindividual interleukin-6 variations on the cardiovascular prognosis of patients with chronic renal diseaseAcute kidney failure in the context of a Tako-Tsubo syndrome[Cardiac markers in different degrees of chronic kidney disease: influence of inflammation and previous heart disease]
P50
Q26864133-16DD560E-D5E7-429B-9270-32516ADE5981Q30893344-2A4C41EA-8D90-4B3C-A56E-34259ADD327AQ33403445-B799ACAC-715C-4EAC-8DFA-70EFBE3583C4Q33437634-7847B094-63B0-4FAB-89EE-00020B17368AQ34161521-9620C585-D73C-4868-B311-1D09A528231BQ37497101-FCCBDF4E-273B-4EB4-8091-62A90E4652C3Q38403392-59F32903-3EC1-40FB-9DD1-5F51AECA2975Q38572321-D1BB2973-3826-41D8-B013-88050A76A7FDQ39802453-A1DA28AD-F011-43BF-85F8-D95AD852C6F5Q40080979-8F12E62C-7011-4843-8A7C-5FF63B7EF95CQ40245790-9A79FB2D-7996-4990-A3A6-AA8ACBEE6403Q40540451-9370E631-1CB7-4115-99FF-8D1826A4D5A7Q40846260-C08AD546-27FD-41D2-9CAF-8DE9731FEECDQ41100438-B64B9AE2-7C5F-4BA2-81F1-89AEDEEB4B9AQ41975971-B8D428DA-956A-4031-BE9C-44F889EAF173Q43889933-F04DE7B6-C0EA-4DE5-AEDA-808E3BB1B910Q43910176-DE569AB4-59AB-44E1-8BD5-641A7DCF97D3Q43956069-C58576E5-32DE-43BB-961F-2C373729F05EQ43968671-1D3313B5-5D50-447D-A214-DB67B3946EC0Q44864320-30597E42-A9B8-4A33-9E24-26FAA099976AQ47989402-4CF5BB08-9103-4A0B-8DE1-32E6969D51EDQ48135919-CC2875B3-0CD3-4966-BAB2-A2A8225397BEQ48256558-824D43F6-6960-47D4-A62C-37E2EAC25A91Q50926275-252AB19B-8043-489A-954A-2CAE1E236AF3Q51139349-FBB594D5-B317-482B-8719-D974B75423CFQ51451952-39FCC743-0300-4661-AD01-3736DBAEE78AQ51535664-620F6A41-F84F-4027-BCB9-F8B4F3CB15DEQ52944898-F05A4FD0-B509-4B7F-87E6-29098DF2FCCDQ53776721-48FE60EA-84B2-4CA3-8F13-B78E7CA8E7DEQ54123199-D720E356-835F-4E0F-BDA3-13C7BC011073Q54225958-A2254011-3A5C-431A-9070-01D9CD4F75B9Q54452427-D4E0E0F2-726D-4E66-AC5B-7093A15157CAQ54472170-5AE3D4FD-D720-484A-A88C-9E5E77D04E08Q62808058-5471B97B-DBED-4D16-87C0-2019A94CC0C8Q63684334-B5A4219C-C79B-4C92-B6FB-18DFF8CAD558Q83678301-D2549743-327B-4811-B737-6F63E239F931Q83784506-1362CD62-D18B-4398-9C09-376E6A65C89FQ84495711-79046333-D2B4-4A80-942B-87D405623E29Q84520831-491CC2BA-0E26-40ED-BE6B-4E51AAD13982Q84635338-7902B118-6525-43D9-8F00-707C1F6A89C0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Borja Quiroga
@ast
Borja Quiroga
@en
Borja Quiroga
@es
Borja Quiroga
@nl
Borja Quiroga
@sl
type
label
Borja Quiroga
@ast
Borja Quiroga
@en
Borja Quiroga
@es
Borja Quiroga
@nl
Borja Quiroga
@sl
prefLabel
Borja Quiroga
@ast
Borja Quiroga
@en
Borja Quiroga
@es
Borja Quiroga
@nl
Borja Quiroga
@sl
P106
P21
P31
P496
0000-0001-5730-1929